Rhumbline Advisers Has $1.99 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Rhumbline Advisers boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 2.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 237,913 shares of the company’s stock after buying an additional 5,649 shares during the quarter. Rhumbline Advisers owned approximately 0.08% of Amneal Pharmaceuticals worth $1,994,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of Amneal Pharmaceuticals by 5,975.0% during the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company’s stock worth $26,000 after acquiring an additional 3,107 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $52,000. Straightline Group LLC acquired a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth $92,000. Brevan Howard Capital Management LP bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth $107,000. Finally, Cibc World Markets Corp bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth $118,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Up 4.6%

Amneal Pharmaceuticals stock opened at $8.11 on Tuesday. Amneal Pharmaceuticals, Inc. has a 52 week low of $6.29 and a 52 week high of $9.48. The business has a 50-day simple moving average of $7.43 and a 200 day simple moving average of $7.93. The stock has a market cap of $2.54 billion, a price-to-earnings ratio of -11.93 and a beta of 1.05.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.05. The firm had revenue of $695.42 million during the quarter, compared to analysts’ expectations of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. On average, research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Analysts Set New Price Targets

AMRX has been the subject of a number of analyst reports. Wall Street Zen downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 13th. The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a research report on Friday, June 6th. They set a “buy” rating and a $12.00 target price on the stock. Barclays lifted their price target on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Amneal Pharmaceuticals has an average rating of “Buy” and an average price target of $11.60.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.